Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV

Jain, Mamta K.; Zoellner, Cindy

doi:10.1097/qad.0b013e3282f1e769

Cited by 21 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar clinical findings have been described by others [46]. However, in an individual with HIV/HBV/ hepatitis delta virus (HDV) coinfection, ETV monotherapy did not cause any significant change in plasma HIV-RNA nor did it select for the M184V mutation in HIV after 24 weeks of treatment [47].…”

Section: Entecavirsupporting

confidence: 76%

Management of hepatitis B virus co-infection on and off antiretroviral therapy

Soriano¹,

Vispo²,

Bottecchia³

et al. 2008

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is recognized in 5% to 10% of persons with HIV. Co-infected individuals show an accelerated course of HBV-associated liver disease with faster progression to cirrhosis. The number of anti-HBV drugs has increased in the past few years, and some agents (eg, lamivudine, emtricitabine, tenofovir) also exert activity against HIV-1. Emergence of drug resistance challenges the long-term benefit of anti-HBV monotherapy. Data derived from studies using new more potent anti-HBV drugs are very promising, and strategies to use these antiretrovirals sequentially or in combination are being developed. Appropriate diagnosis and monitoring of chronic hepatitis B, including the use of noninvasive tools for assessing liver fibrosis, measurement of serum HBV-DNA, and drug-resistance testing, along with wise use of antivirals may convert HBV/HIV co-infection in to a manageable disease. Hopefully, this success will translate into a halt of liver-related complications and death in the co-infected population.

show abstract

Section: Entecavirsupporting

confidence: 76%

Management of hepatitis B virus co-infection on and off antiretroviral therapy

Soriano¹,

Vispo²,

Bottecchia³

et al. 2008

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

show abstract

“…83,84 Therefore, treatment choices for patients coinfected with HIV and HBV need to be made carefully to avoid inadvertent monotherapy for either infection and the possible development of HBV and/or HIV drug resistance.…”

Section: Hepatitis Bmentioning

confidence: 99%

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines

Tseng

Foisy

Hughes

et al. 2012

CJHP

View full text Add to dashboard Cite

“…ETV is not recommended for HIV/HBV co-infected patients because it can lead to the emergence of the HIV M184V mutation (McMahon et al, 2007, Jain and Zoellner, 2007). …”

Section: Nrtismentioning

confidence: 99%

Antiviral therapies: Focus on hepatitis B reverse transcriptase

Michailidis

Kirby

Hachiya

et al. 2012

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is the etiologic agent of mankind’s most serious liver disease. While the availability of a vaccine has reduced the number of new HBV infections, the vaccine does not benefit the approximately 350 million people already chronically infected by the virus. Most of the drugs approved by the FDA for the treatment of hepatitis B target the reverse transcriptase (RT or P gene product) and are nucleoside RT inhibitors (NRTIs) that suppress viral replication. However, prolonged monotherapies directed against a single target result in the emergence of viral resistance. HBV genotypic differences affect NRTI resistance, and because the reading frames of the S (surface antigen) and P genes partially overlap, genomic differences that affect the surface of the virus may also alter the viral polymerase sequence, function and drug susceptibility. The scope of this review is to assess the effects of HBV genotypic variation on the development of drug resistance to NRTIs. Some RT residues that vary among different genotypes are in the vicinity of residues that mutate and give rise to NRTI resistance. Interactions between these amino acids can help explain the effect of HBV genotype on the development of NRTI resistance during antiviral therapies, and might help in the design of improved therapeutic strategies.

show abstract

Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV

Cited by 21 publications

References 2 publications

Management of hepatitis B virus co-infection on and off antiretroviral therapy

Management of hepatitis B virus co-infection on and off antiretroviral therapy

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines

Antiviral therapies: Focus on hepatitis B reverse transcriptase

Contact Info

Product

Resources

About